We will be starting a weekly update from Cleveland HeartLab! Tune in and "know your risk"!
"While routine lipid screening plays an important role in cardiovascular risk assessment it does not provide a complete picture of your health. In fact, nearly 50% of all heart attacks and strokes occur in patients with ‘normal’ cholesterol levels.Recent evidence goes beyond lipids to suggest that inflammation within the artery wall is the primary contributor to this residual risk for heart attack and stroke. Inflammation contributes to both vulnerable plaque formation and to plaque rupture.
Inflammation can be easily measured with advanced testing that assesses a patient’s inflammatory state and cardiovascular risk. Monitoring their inflammatory status may allow you to catch the beginning, or even treat advanced stages of inflammation, in an effort to reduce their cardiovascular risk.
Cleveland HeartLab offers unique inflammation testing which provides additional and complementary insight into cardiovascular risk beyond cholesterol testing alone. Our inflammation testing consists of simple blood and urine biomarkers that identify inflammatory risk across a risk spectrum. This additional information allows for targeted treatment to reduce risk over one’s lifetime.
This group of tests covers a patient’s biomarker profile which may result from lifestyle concerns (F2-IsoPs, OxLDL) to the development of metabolic or cardiovascular disease (ADMA/SDMA, Microalbumin, hsCRP) and formation of vulnerable plaque and increased risk for an adverse event (Lp-PLA2 Activity, MPO)."